In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Experts from NYU Langone Heart will present the latest advancements in cardiovascular science and clinical care at the 2024 American Heart Association's Scientific Sessions, held from November 16 to ...